References

nid

Нефрология и диализ

Nephrology and Dialysis

1680-44222618-9801

Российское диализное общество

nid-564

Research Article

ОБЗОРЫ И ЛЕКЦИИ

REVIEWS AND LECTURES

Клеточные технологии в трансплантации почки

Cell technologies in renal transplantation

Момыналиев

К. Т.

Momynaliev

K. T.

dhoroshun@gmail.com

Огай

В. Б.

Ogay

V. B.

noemail@neicon.ru

Хорошун

Е. В.

Khoroshun

E. V.

noemail@neicon.ru

Бабенко

Н. Н.

Babenko

N. N.

noemail@neicon.ru

Каабак

М. М.

Kaabak

M. M.

noemail@neicon.ru

Евразийский национальный университет им. Л.Н. Гумилева. Астана, Республика КазахстанРоссияL.N. Gumilyov Eurasian National University. Astana, Republic KazakhstanRussian Federation

РГП «Национальный центр биотехнологии». Астана, Республика КазахстанРоссияNational Center for Biotechnology. Astana, Republic KazakhstanRussian Federation

Лаборатория Ситилаб. Москва, РоссияРоссияLaboratory CityLab. Moscow, RussiaRussian Federation

Российский научный центр хирургии им. академика Б.В. Петровского, Российская академия медицинских наук. Москва, РоссияРоссияB.V. Petrovsky Russian scientific center of surgery, Russian Academy of Medical Sciences. Moscow, RussiaRussian Federation

2014

13092024

164439452

2024

Момыналиев К.Т., Огай В.Б., Хорошун Е.В., Бабенко Н.Н., Каабак М.М.

Momynaliev K.T., Ogay V.B., Khoroshun E.V., Babenko N.N., Kaabak M.M.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://journal.nephro.ru/jour/article/view/564

В настоящее время трансплантация почки прочно утвердилась в качестве основного метода заместительной терапии при хронической почечной недостаточности в терминальной стадии. Благодаря современным иммунодепрессантам, резко повысилась краткосрочная выживаемость пациентов и трансплантата. Однако долгосрочная выживаемость аллотрансплантата почки не улучшается такими же темпами. Хроническая нефропатия аллотрансплантата остается наиболее частой причиной потери трансплантата, тогда как сердечно-сосудистые заболевания остаются ведущей причиной смертности пациентов после трансплантации. Для улучшения результатов трансплантации важно продолжать разработку новых стратегий профилактики острых и хронических отторжений, в том числе за счет уменьшения необходимости пожизненной иммуносупрессии и повышения донор-специфической толерантности. В данном обзоре рассматриваются различные стратегии использования клеточных технологий в применении к пересадке почки. Использование мезенхимальных стволовых клеток (МСК) среди всех клеточных технологий при трансплантации почки является перспективной терапевтической стратегией для управления возникновения и прогрессирования болезни «трансплантат против хозяина». Предварительные данные свидетельствуют о том, что использование МСК может обеспечить потенциальные выгоды в трансплантации почки за счет уменьшения дозы иммуносупрессивных препаратов, которое необходимо для поддержания долгосрочного выживания и функции трансплантата после операции.

Currently, renal transplantation has firmly established as the main method of replacement therapy in patients with the end stage chronic renal disease. Thanks to modern immunosuppressive drugs, short-term graft and patient survival are dramatically increased. However, long-term renal allograft survival has improved in a lesser extent. Chronic allograft nephropathy is the most common cause of graft failure, whereas cardiovascular diseases remain the leading cause of death among patients receiving renal transplantation. To improve the results of transplantation, it is important to continue developing new strategies for the prevention of acute and chronic rejection. Two of such strategies are reducing the need for lifelong immunosuppressive therapy and enhancing donor-specific tolerance. This paper reviews different strategies of using cellular technology in renal transplantation. The use of mesenchymal stem cells (MSCs) is a promising therapeutic strategy for controlling the onset and progression of the «graft versus host disease». Preliminary data indicate that the use of MSCs can provide potential benefits in renal transplantation by reducing the doses of immunosuppressive drugs required for maintaining the long-term survival and graft function after surgery.

мезенхимальные стволовые клеткирегуляторные Т-клеткидендритные клеткииммунологическая толерантностьтрансплантация почкиmesenchymal stem cellsregulatory T-cellsdendritic cellsimmunological tolerancerenal transplantation

References1

Aggarwal S., Pittenger M.F. Human mesenchymal stem cells modulate allogeneic immune cell responses // Blood. 2005. Vol. 105. P. 1815-1822.

Aiello S., Cassis P., Cassis L. et al. DnIKK2-transfected dendritic cells induce a novel population of inducible nitric oxide synthase-expressing CD4+CD25- cells with tolerogenic properties // Transplantation. 2007. Vol. 83. P. 474-484.

Atoui R., Chiu R.C. Concise review: immunomodulatory properties of mesenchymal stem cells in cellular transplantation: update, controversies, and unknowns // Stem Cells Transl. Med. 2012. Vol. 1. P. 200-205.

Bach J.F. Induction of immunological tolerance using monoclonal antibodies: applications to organ transplantation and autoimmune disease // C. R. Biol. 2006. Vol. 329. P. 260-262.

Banchereau J., Steinman R.M. Dendritic cells and the control of immunity // Nature. 1998. Vol. 392. P. 245-252.

Battaglia M., Stabilini A., Roncarolo M.G. et al. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells // Blood. 2005. Vol. 105. P. 4743-4748.

Batten P., Sarathchandra P., Antoniw J.W. et al. Human mesenchymal stem cells induce T cell anergy and downregulate T cell allo-responses via the TH2 pathway: relevance to tissue engineering human heart valves // Tissue Eng. 2006. Vol. 12. P. 2263-2273.

Bieback K., Kern S., Kl¨uter H., et al. Critical parameters for the isolation of mesenchymal stem cells from umbilical cord blood // Stem Cells. 2004. Vol. 22. P. 625-634.

Bischoff D.S., Zhu J.H., Makhijani N.S. et al. Acidic pH stimulates the production of the angiogenic CXC chemokine, CXCL8 (interleukin-8), in human adult mesenchymal stem cells via the extracellular signal-regulated kinase, p38 mitogen-activated protein kinase, and NF-kappaB pathways // J. Cell. Biochem. 2008. Vol. 104. P. 1378-1392.

Briggs J.D. Causes of death after renal transplantation // Nephrol. Dial. Transplant. 2001. Vol.16. P.1545-1549.

Bunnag S., Allanach K., Jhangri G.S. et al. FOXP3 expression in human kidney transplant biopsies is associated with rejection and time post transplant but not with favorable outcomes // Am. J. Transplant. 2008. Vol. 8. P. 1423-1433.

Campagnoli C., Roberts I.A., Kumar S. et al. Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow // Blood. 2001. Vol. 98. P. 2396-2402.

Caplan A.I. Mesenchymal stem cells // J. Orthop. Res. 1991. Vol. 9. P. 641-650.

Casiraghi F., Todeschini M., Remuzzi G. Mesenchymal stromal cells to promote solid organ transplantation tolerance // European. Nephrology. 2011. Vol. 5. P. 61-67.

Casiraghi F., Azzollini N., Cassis P. et al. Pre-transplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells // J. Immunol. 2008. Vol. 81. P. 3933-3946.

Casiraghi F., Azzollini N., Todeschini M. et al. Localization of mesenchymal stromal cells dictates their immune or proinflammatory effects in kidney transplantation // Am. J. Transplant. 2012. Vol. 12. P. 2373-2383.

Cavinato R.A., Casiraghi F., Azzollini N. et al. Pretransplant donor peripheral blood mononuclear cells infusion induces transplantation tolerance by generating regulatory T cells // Transplantation. 2005. Vol. 79. P. 1034-1039.

Chabannes D., Hill M., Merieau E. et al. A role for heme oxygenase-1 in the immunosuppressive effect of adult rat and human mesenchymal stem cells // Blood. 2007. Vol. 110. P. 3691-3694.

Collison L.W., Workman C.J., Kuo T.T. et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function // Nature. 2007. Vol. 450. № 7169. P. 566-569.

Crisan M., Yap S., Casteilla L. et al. A perivascular origin for mesenchymal stemcells in multiple human organs // Cell. Stem Cell. 2008. Vol. 3. P. 301-313.

Dahl S.R., Kleiveland C.R., Kassem M. et al. Determination of thromboxanes, leukotrienes and lipoxins using high-temperature capillary liquid chromatography-tandem mass spectrometry and on-line sample preparation // J Chromatogr. A. 2009. Vol. 1216. P. 4648-4654.

De Bari C., Dell’Accio F., Tylzanowski P. et al. Multipotent mesenchymal stem cells from adult human synovial membrane // Arthritis. Rheum. 2001. Vol. 44. P. 1928-1942.

Deaglio S., Dwyer K.M., Gao W. et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression // J. Exp. Med. 2007. Vol. 204. P. 1257-1265.

Diethelm A.G., Deierhoi M.H., Hudson S.L. et al. Progress in renal transplantation. A single center study of 3359 patients over 25 years // Ann. Surg. 1995. Vol. 221. P. 446-457.

Djouad F., Charbonnier L.M., Bouffi C. et al. Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism // Stem Cells. 2007. Vol. 25. P. 2025-2032.

Dominici M., Le Blanc K., Mueller I. et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement // Cytotherapy. 2006. Vol. 8. P. 315-317.

Durrbach A., Francois H., Beaudreuil S. et al. Advances in immunosuppression for renal transplantation // Nat. Rev. Nephrol. 2010. Vol. 6. P. 160-167.

Eggenhofer E., Renner P., Soeder Y. et al. Features of synergism between mesenchymal stem cells and immunosuppressive drugs in a murine heart transplantation model // Transpl Immunol. 2011. Vol. 25. P. 141-147.

English K., Barry F.P., Field-Corbett C.P. et al. IFN-gamma and TNF-alpha differentially regulate immunomodulation by murine mesenchymal stem cells // Immunol. Lett. 2007. Vol. 110. P. 91-100.

English K., Barry F.P., Mahon B.P. Murine mesenchymal stem cells suppress dendritic cell migration, maturation and antigen presentation // Immunol. Lett. 2008. Vol. 115. P. 50-58.

English K., French A., Wood K.J. Mesenchymal stromal cells: facilitators of successful transplantation? // Cell Stem Cell. 2010. Vol. 7. P. 431-442.

English K., Ryan J.M., Tobin L. et al. Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25(High) forhead box P3+ regulatory T cells // Clin. Exp. Immunol. 2009. Vol. 156. P. 149-160.

Friedenstein A.J., Gorskaja J.F., Kulagina N.N. Fibroblast precursors in normal and irradiated mouse hematopoietic organs // Exp Hematol. 1976. Vol. 4. P. 267-274.

Fudaba Y., Spitzer T.R., Shaffer J. et al. Myeloma responses and tolerance following combined kidney and nonmyeloablative marrow transplantation: in vivo and in vitro analyses // Am. J. Transplant. 2006. Vol. 6. P. 2121-2133.

Garin M.I., Chu C.C., Golshayan D. et al. Galectin-1: a key effector of regulation mediated by CD4+CD25+ T cells // Blood. 2007. Vol. 109. P. 2058-2065.

Ge W., Jiang J., Arp J. et al. Regulatory T-cell generation and kidney allograft tolerance induced by mesenchymal stem cells associated with indoleamine 2,3-dioxygenase expression // Transplantation. 2010. Vol. 90. P. 1312-1320.

Ge W., Jiang J., Baroja M.L. et al. Infusion of mesenchymal stem cells and rapamycin synergize to attenuate alloimmune responses and promote cardiac allograft tolerance // Am. J. Transplant. 2009. Vol. 9. P. 1760-1772.

Golshayan D., Jiang S., Tsang J. et al. In vitro-expanded donor alloantigen-specific CD4+CD25+ regulatory T cells promote experimental transplantation tolerance // Blood. 2007. Vol. 109. P. 827-835.

Grimbert P., Mansour H., Desvaux D. et al. The regulatory/cytotoxic graft-infiltrating T cells differentiate renal allograft borderline change from acute rejection // Transplantation. 2007. Vol. 83. P. 341-346.

Howard R.J., Patton, P.R., Reed A.I. et al. The changing causes of graft loss and death after kidney transplantation // Transplantation. 2002. Vol. 73. P. 1923-1928.

Huang H., Kim H.J., Chang E.J. et al. IL-17 stimulates the proliferation and differentiation of human mesenchymal stem cells: implications for bone remodeling // Cell Death Differ. 2009. Vol. 16. P. 1332-1343.

In’t Anker P.S., Scherjon S.A., Kleijburg-van der Keur C. et al. Isolation of mesenchymal stem cells of fetal or maternal origin from human placenta // Stem Cells. 2004.Vol. 22. P. 1338-1345.

Inoue S., Popp F.C., Koehl G.E. et al. Immunomodulatory effects of mesenchymal stem cells in a rat organ transplant model // Transplantation. 2006. Vol. 81. P. 1589-1595.

Jevnikar A.M., Mannon R.B. Late kidney allograft loss: what we know about it, and what we can do about it // Clin. J. Am. Soc.Nephrol. 2008. Vol. 3 (Suppl. 2). P. S56-67.

Jiang X.X., Zhang Y., Liu B. et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells // Blood. 2005. Vol. 105. P. 4120-4126.

Karlsson H., Samarasinghe S., Ball L.M. et al. Mesenchymal stem cells exert differential effects on alloantigen and virus-specific T-cell responses // Blood. 2008. Vol. 112. P. 532-541.

Kawai T., Cosimi A.B., Spitzer T.R. et al. HLA-mismatched renal transplantation without maintenance immunosuppression // N. Engl. J. Med. 2008. Vol. 358. P. 353-361.

Kawai T., Sachs D.H., Sykes M. et al. HLA-mismatched renal transplantation without maintenance immunosuppression // N. Engl. J.Med. 2013. Vol. 368. Р.1850-1852.

Kim Y.H., Wee Y.M., Choi M.Y. et al. Interleukin (IL)-10 induced by CD11b(+) cells and IL-10-activated regulatory T cells play a role in immune modulation of mesenchymal stem cells in rat islet allografts // Mol. Med. 2011. Vol. 17. P. 697-708.

Kingsley C.I., Karim M., Bushell A.R. et al. CD25+CD4+ regulatory T cells prevent graft rejection: CTLA-4- and IL-10-dependent immunoregulation of alloresponses // J. Immunol. 2002. Vol. 168. P. 1080-1086.

Kingsley C.I., Nadig S.N., Wood K.J. Transplantation tolerance: lessons from experimental rodent models // Transpl. Int. 2007. Vol. 20. P. 828-841.

Kirk A.D. Induction immunosuppression // Transplantation. 2006. Vol. 82. P. 593-602.

Kirk A.D., Hale D.A., Mannon R.B. et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H) // Transplantation. 2003. Vol. 76. P. 120-129.

Kirk A.D., Mannon R.B., Kleiner D.E. et al. Results from a human renal allograft tolerance trial evaluating T-cell depletion with alemtuzumab combined with deoxyspergualin // Transplantation. 2005. Vol. 80. P. 1051-1059.

Krampera M., Glennie S., Dyson J. et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide // Blood. 2003. Vol. 101. P. 3722-3729.

Kuo Y.R., Wang C.T., Cheng J.T. et al. Bone marrow-derived mesenchymal stem cells enhanced diabetic wound healing through recruitment of tissue regeneration in a rat model of treptozotocin-induced diabetes // Plastic and Reconstructive Surgery. 2011. Vol. 128. P. 872-880.

Le Blanc K., Frassoni F., Ball L. et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study // Lancet. 2008. Vol. 371. P. 1579-1586.

Lechler R.I., Garden O.A., Turka L.A. The complementary roles of deletion and regulation in transplantation tolerance // Nat. Rev. Immunol. 2003. Vol. 3. P. 147-158.

Lee H., Park J.B., Lee S. et al. Intra-osseous injection of donor mesenchymal stem cell (MSC) into the bone marrow in living donor kidney transplantation: a pilot study // J. Transl. Med. 2013. Vol. 11. P. 96-104.

Leventhal J., Abecassis M., Miller J. et al. Chimerism and tolerance without GVHD or engraftment syndrome in HLA-mismatched combined kidney and hematopoietic stem cell transplantation // Sci. Transl. Med. 2012. Vol. 4. P. 124-128.

Li M., Zhang X., Zheng X. et al. Immune modulation and tolerance induction by RelB-silenced dendritic cells through RNA interference // J. Immunol. 2007. Vol. 178. P. 5480-5487.

Li Y.P., Paczesny S., Lauret E. et al. Human mesenchymal stem cells license adult CD34+ hemopoietic progenitor cells to differentiate into regulatory dendritic cells through activation of the Notch pathway // J. Immunol. 2008. Vol. 180. P. 1598-608.

Liu C., Zhu P., Saito T. et al. Non-myeloablative conditioning is sufficient to induce mixed chimerism and subsequent acceptance of donor specific cardiac and skin grafts // Int. Immunopharmacol. 2013. Vol.16. P. 392-398.

Longoni B., Szilagyi E., Puviani L. et al. Mesenchymal stem cell-based immunomodulation in allogeneic heterotopic heart-lung transplantation // J. Transplant. Technol. Res. 2012. Vol. 2. P. 107.

Lutz M.B., Suri R.M., Niimi M. et al. Immature dendritic cells generated with low doses of GM-CSF in the absence of IL-4 are maturation resistant and prolong allograft survival in vivo // Eur. J. Immunol. 2000. Vol. 30. P. 1813-1822.

Martin L., Funes de la Vega M., Bocrie O. et al. Detection of Foxp3+ cells on biopsies of kidney transplants with early acute rejection // Transplant. Proc. 2007. Vol. 39. P. 2586-2588.

Meier-Kriesche H.U., Schold J.D., Srinivas T.R. et al. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era // Am. J. Transplant. 2004. Vol. 4. Р. 378-383.

Meisel R., Zibert A., Laryea M. et al. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation // Blood. 2004. Vol. 103. P. 4619-4621.

Mellman I., Steinman R.M. Dendritic cells: specialized and regulated antigen processing machines // Cell. 2001. Vol. 106. P. 255-258.

Millan M.T., Shizuru J.A., Hoffmann P. et al. Mixed chimerism and immunosuppressive drug withdrawal after HLA-mismatched kidney and hematopoietic progenitor transplantation // Transplantation. 2002. Vol. 73. P. 1386-1391.

Morelli A.E., Thomson A.W. Tolerogenic dendritic cells and the quest for transplant tolerance // Nat. Rev. Immunol. 2007. Vol. 7. P. 610-621.

Morita H., Sugiura K., Inaba M. et al. A strategy for organ allografts without using immunosuppressants or irradiation // Proc. Natl. Acad. Sci. U S A. 1998. Vol. 95. P. 6947-52.

Murray J.E., Merrill J.P., Harrison J.H. Kidney transplantation between seven pairs of identical twins // Ann Surg. 1958. Vol. 148. Р. 343-459.

Muthukumar T., Dadhania D., Ding R. et al. Messenger RNA for FOXP3 in the urine of renal-allograft recipients // N. Engl. J. Med. 2005. Vol. 353. P. 2342-2351.

Naka E.L., Ponciano V.C., Rangel E.B. et al. FOXP3-positive regulatory cells inside the allograft and the correlation with rejection // Transplant. Proc. 2006. Vol. 38. P. 3202-3204.

Nauta A.J., Kruisselbrink A.B., Lurvink E. et al. Mesenchymal stem cells inhibit generation and function of both CD34+-derived and monocyte-derived dendritic cells // J. Immunol. 2006. Vol. 177. P. 2080-2087.

Noris M., Casiraghi F., Todeschini M. et al. Regulatory T cells and T cell depletion: role of immunosuppressive drugs // J. Am. Soc. Nephrol. 2007. Vol. 18. P. 1007-1018.

Ojo A.O., Hanson J.A., Wolfe R.A. et al. Long-term survival in renal transplant recipients with graft function // Kidney Int. 2000. Vol. 57. P. 307-313.

Ophir E., Reisner Y. The use of donor-derived veto cells in hematopoietic stem cell transplantation // Front. Immunol. 2012. Vol. 3. P. 93.

Perico N., Casiraghi F., Introna M. et al. Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility // Clin J Am Soc Nephrol. 2011. Vol. 6. P. 412-422.

Pittenger M.F., Mackay A.M., Beck S.C. et al. Multilineage potential of adult human mesenchymal stem cells // Science. 1999. Vol. 284. P. 143-147.

Popp F.C., Eggenhofer E., Renner P. et al. Mesenchymal stem cells can induce long-term acceptance of solid organ allografts in synergy with low-dose mycophenolate // Transpl Immunol. 2008. Vol. 20. P. 55-60.

Prommool S., Jhangri G.S., Cockfield S.M. et al. Time dependency of factors affecting renal allograft survival // J. Am. Soc. Nephrol. 2000. Vol. 11. P. 565-573.

Remuzzi G., Perico N., Carpenter C.B. et al. The thymic way to transplantation tolerance // J. Am. Soc. Nephrol. 1995. Vol. 5. P. 1639-1646.

Ren G., Su J., Zhang L. et al. Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression // Stem Cells. 2009. Vol. 27. P. 1954-1962.

Ruggenenti P., Perico N., Gotti E. et al. Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury // Transplantation. 2007. Vol. 84. P. 956-964.

Sakaguchi S. Regulatory T cells in the past and for the future // Eur. J. Immunol. 2008. Vol. 38. P. 901-937.

Salama A.D., Remuzzi G., Harmon W.E. et al. Challenges to achieving clinical transplantation tolerance // J. Clin. Invest. 2001. Vol. 108. P. 943-948.

Sato K., Ozaki K., Oh I. et al. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells // Blood. 2007. Vol. 109. P. 228-234.

Sayegh M.H., Remuzzi G. Clinical update: immunosuppression minimisation // Lancet. 2007. Vol. 369. P. 1676-1678.

Schweitzer E.J., Matas A.J., Gillingham K.J. et al. Causes of renal allograft loss. Progress in the 1980s, challenges for the 1990s // Ann. Surg. 1991. Vol. 214. P. 679-688.

Tan J., Wu W., Xu X. et al. Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial // JAMA. 2012. Vol. 307. P. 1169-1177.

Taner T., Hackstein H., Wang Z. et al. Rapamycin-treated, alloantigen-pulsed host dendritic cells induce ag-specific T cell regulation and prolong graft survival // Am. J. Transplant. 2005. Vol. 5. P. 228-236.

Tang Q., Bluestone J.A. The Foxp3+ regulatory T cell: a jack of all trades, master of regulation // Nat. Immunol. 2008. Vol. 9. P. 239-244.

Thornton A.M., Shevach E.M. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production // J. Exp. Med. 1998. Vol. 188. P. 287-296.

Tolar J., Le Blanc K., Keating A. et al. Concise review: hitting the right spot with mesenchymal stromal cells // Stem Cells. 2010. Vol. 28. P. 1446-1455.

Tomasoni S., Aiello S., Cassis L. et al. Dendritic cells genetically engineered with adenoviral vector encoding dnIKK2 induce the formation of potent CD4+ T-regulatory cells // Transplantation. 2005. Vol. 79. P. 1056-1061.

Uccelli A., Moretta L., Pistoia V. Mesenchymal stem cells in health and disease // Nat. Rev. Immunol. 2008. Vol. 8. P. 726-736.

100

Van Parijs L., Abbas, A.K. Homeostasis and self-tolerance in the immune system: turning lymphocytes off // Science. 1998. Vol. 280. P. 243-248.

101

Van Parijs L., Perez V.L., Abbas A.K. Mechanisms of peripheral T cell tolerance // Novartis. Found. Symp. 1998. Vol. 215. P. 5-14.

102

Veronese F., Rotman S., Smith R.N. et al. Pathological and clinical correlates of FOXP3+ cells in renal allografts during acute rejection // Am. J. Transplant. 2007. Vol. 7. P. 914-922.

103

Waldmann H., Adams E., Fairchild P. et al. Regulation and privilege in transplantation tolerance // J. Clin. Immunol. 2008. Vol. 28. P. 716-725.

104

Wang Q., Sun B., Wang D. et al. Murine bone marrow mesenchymal stem cells cause mature dendritic cells to promote T-cell tolerance // Scand. J. Immunol. 2008. Vol. 68. P. 607-615.

105

Wang Y., Zhang A., Ye Z. et al. Bone marrow-derived mesenchymal stem cells inhibit acute rejection of rat liver allografts in association with regulatory T-cell expansion // Transplant. Proc. 2009. Vol. 41. P. 4352-4356.

106

Wang Z., Shi B., Jin H. et al. Low-dose of tacrolimus favors the induction of functional CD4(+)CD25(+)FoxP3(+) regulatory T cells in solid-organ transplantation // Int. Immunopharmacol. 2009. Vol. 9. P. 564-569.

107

Wing K., Onishi Y., Prieto-Martin P. et al. CTLA-4 control over Foxp3+ regulatory T cell function // Science. 2008. Vol. 322. P. 271-275.

108

Xu D.M., Yu X.F., Zhang D. et al. Mesenchymal stem cells differentially mediate regulatory T cells and conventional effector T cells to protect fully allogeneic islet grafts in mice // Diabetologia. 2012. Vol. 55. P. 1091-1102.

109

Zeiser R., Nguyen V.H., Beilhack A. et al. Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production // Blood. 2006. Vol. 108. P. 390-399.

110

Zhang B., Liu R., Shi D. et al. Mesenchymal stem cells induce mature dendritic cells into a novel Jagged-2-dependent regulatory dendritic cell population // Blood. 2009. Vol. 113. P. 46-57.

111

Zhang W., Ge W., Li C. et al. Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells // Stem Cells Dev. 2004. Vol. 13. P. 263-271.

112

Zhang W., Qin C., Zhou Z.M. Mesenchymal stem cells modulate immune responses combined with cyclosporine in a rat renal transplantation model // Transplant. Proc. 2007. Vol. 39. P. 3404-3408.

113

Zhao D.M., Thornton A.M., Di Paolo R.J. et al. Activated CD4+CD25+ T cells selectively kill B lymphocytes // Blood. 2006. Vol. 107. P. 3925-3932.

The authors declare that there are no conflicts of interest present.